MX2018009312A - Celulas presentadoras de antigeno modificadas por ingenieria y usos de las mismas. - Google Patents
Celulas presentadoras de antigeno modificadas por ingenieria y usos de las mismas.Info
- Publication number
- MX2018009312A MX2018009312A MX2018009312A MX2018009312A MX2018009312A MX 2018009312 A MX2018009312 A MX 2018009312A MX 2018009312 A MX2018009312 A MX 2018009312A MX 2018009312 A MX2018009312 A MX 2018009312A MX 2018009312 A MX2018009312 A MX 2018009312A
- Authority
- MX
- Mexico
- Prior art keywords
- presenting cells
- antigen presenting
- engineered antigen
- receptors
- antigen
- Prior art date
Links
- 210000000612 antigen-presenting cell Anatomy 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4614—Monocytes; Macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464469—Tumor associated carbohydrates
- A61K39/464471—Gangliosides, e.g. GM2, GD2 or GD3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
- C07K14/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a receptores de internalización de vesículas extracelulares modificadas por ingeniería genética que tiene la capacidad de mejorar la captación, el procesamiento y la presentación a células T de antígenos asociados a tumores mediante una célula presentadora de antígenos. Se refiere además a vectores o células presentadoras de antígenos que expresan dichos receptores, composición y usos de los mismos para la prevención y/o el tratamiento de un cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16153966.3A EP3202783A1 (en) | 2016-02-02 | 2016-02-02 | Engineered antigen presenting cells and uses thereof |
PCT/EP2017/052145 WO2017134100A1 (en) | 2016-02-02 | 2017-02-01 | Engineered antigen presenting cells and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018009312A true MX2018009312A (es) | 2019-01-28 |
Family
ID=55310688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018009312A MX2018009312A (es) | 2016-02-02 | 2017-02-01 | Celulas presentadoras de antigeno modificadas por ingenieria y usos de las mismas. |
Country Status (11)
Country | Link |
---|---|
US (1) | US11591407B2 (es) |
EP (2) | EP3202783A1 (es) |
JP (1) | JP6989523B2 (es) |
KR (1) | KR20180104146A (es) |
CN (1) | CN108602873A (es) |
AU (1) | AU2017216213B2 (es) |
CA (1) | CA3012574A1 (es) |
IL (1) | IL260905B2 (es) |
MX (1) | MX2018009312A (es) |
SG (1) | SG11201806538WA (es) |
WO (1) | WO2017134100A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
US20210030850A1 (en) * | 2018-04-10 | 2021-02-04 | Northwestern University | Extracellular vesicles comprising targeting affinity domain-based membrane proteins |
CA3097178A1 (en) * | 2018-04-17 | 2019-10-24 | Molecular Templates, Inc. | Her2-targeting molecules comprising de-immunized, shiga toxin a subunit scaffolds |
EP3876977A1 (en) | 2018-11-06 | 2021-09-15 | The Regents Of The University Of California | Chimeric antigen receptors for phagocytosis |
US11026973B2 (en) | 2019-04-30 | 2021-06-08 | Myeloid Therapeutics, Inc. | Engineered phagocytic receptor compositions and methods of use thereof |
CN114173807B (zh) * | 2019-09-02 | 2024-03-19 | 庆北大学校产学协力团 | 包含il-2表面表达-细胞外囊泡作为活性成分的用于预防或治疗癌症的组合物 |
BR112022003970A2 (pt) | 2019-09-03 | 2022-06-21 | Myeloid Therapeutics Inc | Métodos e composições para integração genômica |
KR20220077127A (ko) * | 2019-09-06 | 2022-06-08 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | 암 치료를 위한 키메라 항원 수용체 및 관련 방법 및 조성물 |
US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
EP4076480A4 (en) * | 2019-12-16 | 2024-04-17 | Washington University St Louis | CHIMERIC ANTIGEN RECEPTOR DENDRITIC CELLS (CAR-DCS) AND METHODS OF MAKING AND USING THE SAME |
CN113106067A (zh) * | 2020-01-10 | 2021-07-13 | 南京大学 | 一种嵌合抗原受体-单核/巨噬细胞(car-m)的构建及其应用 |
CA3197423A1 (en) | 2020-11-04 | 2022-05-12 | Daniel Getts | Engineered chimeric fusion protein compositions and methods of use thereof |
US20230071148A1 (en) * | 2021-07-15 | 2023-03-09 | Vcreate, Inc. | Compositions and Methods for Making Novel T-Cell Receptors |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004012817A2 (en) * | 2002-07-31 | 2004-02-12 | Kylix B.V. | Use of genes identified to be involved in tumor development for the development of anti-cancer drugs |
EP1581648A2 (en) * | 2002-09-09 | 2005-10-05 | Nura, Inc. | G protein coupled receptors and uses thereof |
JP2009531022A (ja) * | 2006-02-17 | 2009-09-03 | ラパポート ファミリー インスティテュート フォー リサーチ イン ザ メディカル サイエンシーズ | Ccr5/ccr5リガンド関連疾患を治療するための分子およびその使用方法 |
WO2009003145A1 (en) * | 2007-06-26 | 2008-12-31 | University Of Miami | Antibody-endostatin fusion protein and its variants |
JP2011501946A (ja) | 2007-10-25 | 2011-01-20 | ヴィヴェンティア バイオテクノロジーズ インコーポレーティッド | 変異体HnRNPGの癌関連エピトープに対する抗体およびその使用法 |
JP2011505795A (ja) | 2007-11-27 | 2011-03-03 | ヴィヴェンティア バイオテクノロジーズ インコーポレーティッド | バリアントnfkbibの癌関連エピトープに対する抗体およびその使用 |
WO2010014629A1 (en) * | 2008-07-28 | 2010-02-04 | Trubion Pharmaceuticals, Inc. | Multi-specific binding proteins targeting b cell disorders |
US20110217302A1 (en) * | 2008-10-10 | 2011-09-08 | Emergent Product Development Seattle, Llc | TCR Complex Immunotherapeutics |
WO2010117448A2 (en) * | 2009-04-05 | 2010-10-14 | Provenance Biopharmaceuticals Corp. | Chimeric immunocytokines and methods of use thereof |
TWI507204B (zh) | 2009-05-26 | 2015-11-11 | Oncotherapy Science Inc | Cdc45l胜肽與含此胜肽之疫苗 |
JP2015532306A (ja) * | 2012-10-15 | 2015-11-09 | チューリッヒ大学 | 癌治療のための二重特異性her2リガンド |
EP2777711A1 (en) * | 2013-03-11 | 2014-09-17 | Icon Genetics GmbH | Her2/Neu cancer vaccine |
EP3808410A1 (en) | 2013-12-20 | 2021-04-21 | Cellectis | Method of engineering multi-input signal sensitive t cell for immunotherapy |
CN106573969B (zh) * | 2014-04-10 | 2021-07-30 | 西雅图儿童医院(Dba西雅图儿童研究所) | 药物相关的转基因表达 |
GB201410262D0 (en) * | 2014-06-10 | 2014-07-23 | Cambridge Entpr Ltd | Novel method |
WO2016120217A1 (en) * | 2015-01-26 | 2016-08-04 | Cellectis | Anti-hsp70 specific chimeric antigen receptors (cars) for cancer immunotherapy |
-
2016
- 2016-02-02 EP EP16153966.3A patent/EP3202783A1/en not_active Withdrawn
-
2017
- 2017-02-01 KR KR1020187025166A patent/KR20180104146A/ko not_active Application Discontinuation
- 2017-02-01 JP JP2018558493A patent/JP6989523B2/ja active Active
- 2017-02-01 MX MX2018009312A patent/MX2018009312A/es unknown
- 2017-02-01 CA CA3012574A patent/CA3012574A1/en active Pending
- 2017-02-01 SG SG11201806538WA patent/SG11201806538WA/en unknown
- 2017-02-01 US US16/074,446 patent/US11591407B2/en active Active
- 2017-02-01 EP EP17702860.2A patent/EP3411394A1/en active Pending
- 2017-02-01 AU AU2017216213A patent/AU2017216213B2/en active Active
- 2017-02-01 WO PCT/EP2017/052145 patent/WO2017134100A1/en active Application Filing
- 2017-02-01 CN CN201780009420.8A patent/CN108602873A/zh active Pending
-
2018
- 2018-07-31 IL IL260905A patent/IL260905B2/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL260905B1 (en) | 2024-01-01 |
SG11201806538WA (en) | 2018-08-30 |
WO2017134100A1 (en) | 2017-08-10 |
EP3411394A1 (en) | 2018-12-12 |
CN108602873A (zh) | 2018-09-28 |
AU2017216213B2 (en) | 2021-07-01 |
US20190062450A1 (en) | 2019-02-28 |
JP2019511244A (ja) | 2019-04-25 |
CA3012574A1 (en) | 2017-08-10 |
IL260905A (es) | 2018-09-20 |
US11591407B2 (en) | 2023-02-28 |
AU2017216213A1 (en) | 2018-09-20 |
EP3202783A1 (en) | 2017-08-09 |
IL260905B2 (en) | 2024-05-01 |
JP6989523B2 (ja) | 2022-01-05 |
KR20180104146A (ko) | 2018-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018009312A (es) | Celulas presentadoras de antigeno modificadas por ingenieria y usos de las mismas. | |
MX2023001403A (es) | Neoantigenos y metodos de su uso. | |
CY1121539T1 (el) | Ειδικοι για κλαυδiνη-6 ανοσοϋποδοχεις και επιτοποι τ-κυτταρων | |
PH12018502113A1 (en) | Chimeric receptors and methods of use thereof | |
AU2018253589A1 (en) | Antibodies, pharmaceutical compositions and uses thereof | |
CL2017000278A1 (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t | |
PH12018502225A1 (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
PH12018502478A1 (en) | Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen | |
MX2022004082A (es) | Anticuerpos biespecificos contra cd3 y cd20. | |
PH12017500803A1 (en) | Anti-pd-1 antibodies | |
MX2018012897A (es) | Nuevos polipeptidos biespecificos contra cd137. | |
MX2020010530A (es) | Anticuerpos humanizados contra cd269 (bcma). | |
PH12017502390A1 (en) | Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof | |
MX2017014955A (es) | Agentes de union a inmunorreceptor de celulas t con dominios ig y motivo de inhibicion basado en tirosina de inmunorreceptor (tigit) y usos de los mismos. | |
PH12017500002A1 (en) | Anti-cdh6 antibody drug conjugates | |
MA39819A (fr) | Méthodes et compositions d'immunomodulation | |
MX2016013149A (es) | Produccion de celulas t modificadas, mediante transposon bella durmiente, acoplada con seleccion por metotrexato. | |
MX2018010295A (es) | Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos. | |
WO2018075820A3 (en) | Cereblon-based heterodimerizable chimeric antigen receptors | |
MX362456B (es) | Anticuerpos y vacunas para utilizarse en el tratamiento de canceres por ror1 y para inhibir la metastasis. | |
WO2018187356A3 (en) | Protein antigens and uses thereof | |
AU2016335217A8 (en) | Antigen receptors and uses thereof | |
WO2015179469A3 (en) | Methods and compositions for treating malignancies with dendritic cells | |
AU2016354590A8 (en) | Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy | |
WO2018138681A9 (en) | Hemagglutinin-specific antibodies and uses thereof |